{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:32Z","timestamp":1787004872282,"version":"build-2736575974"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 2 diabetes mellitus affects the quality of life of patients significantly.\n                    Traditional treatments have certain limitations; however, cellular therapy has\n                    demonstrated remarkable positive effects, such as improved blood glucose and\n                    lipid levels, repaired pancreatic and renal structure, and improvements in\n                    diabetic complications. A type 2 diabetes mellitus rat model was constructed,\n                    and rats were divided into six groups. Four groups were further formed to\n                    evaluate the antiinflammatory effects of umbilical cord mesenchymal stem cells.\n                    The antiinflammatory effects of human umbilical cord mesenchymal stem cells were\n                    demonstrated using inflammatory factors and M2 macrophages, a type of\n                    antiinflammatory macrophage. Western blotting and terminal deoxynucleotidyl\n                    transferase-mediated dUTP nick-end labeling staining were performed to further\n                    elaborate the mechanism of action of human umbilical cord mesenchymal stem cells\n                    in type 2 diabetes mellitus treatment. We confirmed that human umbilical cord\n                    mesenchymal stem cells could efficiently treat type 2 diabetes mellitus. We\n                    conducted an ameliorative fasting blood glucose test and an oral glucose\n                    tolerance test and assessed the recovery of liver and renal function using\n                    biochemical factors (such as TC, TG, BUN, and Ccr, among others). The\n                    antiinflammatory effect of the treatment was demonstrated by the increased\n                    expression of biomarkers in M2 macrophages and reduced secretion of inflammatory\n                    cytokines, such as TNF-\u03b1. The regulatory mechanism was involved in the\n                    TLR4\/NF-\u03baB signaling pathway. The apoptosis of pancreatic tissues in type 2\n                    diabetes mellitus was also inhibited by umbilical cord mesenchymal stem cells,\n                    contributing to relief from type 2 diabetes mellitus symptoms. In conclusion,\n                    our findings confirmed that efficient type 2 diabetes mellitus treatment using\n                    human umbilical cord mesenchymal stem cells was related to antiinflammatory\n                    effects mediated via TLR4\/NF-\u03baB signaling inhibition and apoptosis attenuation\n                    in pancreatic tissues.<\/jats:p>","DOI":"10.1055\/a-2695-7019","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T22:53:09Z","timestamp":1757026389000},"page":"688-696","source":"Crossref","is-referenced-by-count":1,"title":["Mechanisms of Action of Umbilical Cord Mesenchymal Stem Cells in Type\n                    2 Diabetes Mellitus Treatment"],"prefix":"10.1055","volume":"57","author":[{"given":"Qiqiang","family":"Tao","sequence":"additional","affiliation":[{"name":"Medical, Beautech Stem Cell Hospital, Qionghai City,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinlei","family":"Lv","sequence":"additional","affiliation":[{"name":"Technology, Beautech Stem Cell Hospital, Qionghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Dong","sequence":"additional","affiliation":[{"name":"Research, Beautech Stem Cell Hospital, Qionghai, China"},{"name":"Institutes of Biological and Medical Sciences, Soochow\n                    University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Li","sequence":"additional","affiliation":[{"name":"Technology, Beautech Stem Cell Hospital, Qionghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Research, Beautech Stem Cell Hospital, Qionghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Technology, Beautech Stem Cell Hospital, Qionghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with\n                    projections of prevalence to 2050: a systematic analysis for the Global Burden\n                    of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s12015-021-10320-w","article-title":"Comparative analysis of the therapeutic effects of amniotic membrane and\n                    umbilical cord derived mesenchymal tem cells for the treatment oftType 2\n                    diabetes","volume":"18","author":"Z Wang","year":"2022","journal-title":"Stem Cell Rev Rep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13287-022-02848-6","article-title":"Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese\n                    adults with type 2 diabetes: a single-center, double-blinded, randomized,\n                    placebo-controlled phase II trial","volume":"13","author":"L Zang","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"ref4","first-page":"8628027","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy ameliorates\n                    nonalcoholic Fftty liver disease in obese type 2 diabetic mice","volume":"2019","author":"B Li","year":"2019","journal-title":"Stem Cells Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/ijms22041546","article-title":"Therapeutic potential of mesenchymal stem cells in a pre-clinical model of\n                    diabetic kidney disease and obesity","volume":"22","author":"C Savio-Silva","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.intimp.2018.04.051","article-title":"The homing of human umbilical cord-derived mesenchymal stem cells and the\n                    subsequent modulation of macrophage polarization in type 2 diabetic mice","volume":"60","author":"Y Yin","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13287-022-02832-0","article-title":"Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy\n                    in a mouse model of type II diabetes mellitus via the PI3K\/AKT signaling\n                    pathway","volume":"13","author":"A Aierken","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.metabol.2016.12.009","article-title":"Metabolic endotoxemia and diabetes mellitus: a systematic review","volume":"68","author":"JM G Gomes","year":"2017","journal-title":"Metabolism"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12886-022-02296-z","article-title":"The role of lipopolysaccharides in diabetic retinopathy","volume":"22","author":"X Qin","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1615\/CritRevBiomedEng.2018027377","article-title":"Human umbilical cord-derived stem cells: isolation, characterization,\n                    differentiation, and application in treating diabetes","volume":"46","author":"B Chandravanshi","year":"2018","journal-title":"Crit Rev Biomed Eng"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-60327-409-8_1","article-title":"In situ detection of apoptosis by the TUNEL assay: an overview of\n                    techniques","volume":"682","author":"D T. Loo","year":"2011","journal-title":"Methods Mol Biol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/14789450.2017.1388167","article-title":"Protein purification and analysis: next generation Western blotting\n                    techniques","volume":"14","author":"M Mishra","year":"2017","journal-title":"Expert Rev Proteomics"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e941918","DOI":"10.12659\/MSM.941918","article-title":"Editorial: First regulatory approval for allogeneic pancreatic islet beta cell\n                    infusion for adult patients with type 1 diabetes mellitus","volume":"29","author":"D V. Parums","year":"2023","journal-title":"Med Sci Monit"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13287-021-02417-3","article-title":"One repeated transplantation of allogeneic umbilical cord mesenchymal stromal\n                    cells in type 1 diabetes: an open parallel controlled clinical study","volume":"12","author":"J Lu","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1021\/acsnano.7b07643","article-title":"Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus\n                    by reversing peripheral insulin resistance and relieving beta-cell\n                    destruction","volume":"12","author":"Y Sun","year":"2018","journal-title":"ACS Nano"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy\n                    in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)","volume":"34","author":"N Perico","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.3390\/ijms20194876","article-title":"Adult stem cell therapeutics in diabetic retinopathy","volume":"20","author":"S Gaddam","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/scd.2016.0275","article-title":"Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear\n                    cell transplantation in type 2 diabetes mellitus: a randomized,\n                    placebocontrolled comparative study","volume":"26","author":"S Bhansali","year":"2017","journal-title":"Stem Cells Dev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11684-011-0116-z","article-title":"Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a\n                    pilot study","volume":"5","author":"R Jiang","year":"2011","journal-title":"Front Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/1574888X13666181002154110","article-title":"Stem cell-based herapies: a new ray of hope for diabetic patients","volume":"14","author":"J Khan","year":"2019","journal-title":"Curr Stem Cell Res Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.12998\/wjcc.v11.i21.5083","article-title":"Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2\n                    diabetes mellitus treatment: a phase 2 clinical trial","volume":"11","author":"X F Lian","year":"2023","journal-title":"World J Clin Cases"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4239\/wjd.v13.i10.877","article-title":"Effectiveness and safety of human umbilical cord-mesenchymal stem cells for\n                    treating type 2 diabetes mellitus","volume":"13","author":"X F Lian","year":"2022","journal-title":"World J Diabetes"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11892-013-0375-y","article-title":"Diabetes mellitus and inflammation","volume":"13","author":"E Lontchi-Yimagou","year":"2013","journal-title":"Curr Diab Rep"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.kint.2022.10.030","article-title":"Targeting inflammation to treat diabetic kidney disease: the road to 2030","volume":"103","author":"S Rayego-Mateos","year":"2023","journal-title":"Kidney Int"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0030-1268413","article-title":"Type 2 diabetes and lipoprotein metabolism affect LPS-induced cytokine and\n                    chemokine release in primary human monocytes","volume":"119","author":"M Bala","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13287-017-0760-6","article-title":"Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal\n                    fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via\n                    the TLR4\/NF-kappaB signaling pathway in vivo and in vitro","volume":"9","author":"B Liu","year":"2018","journal-title":"Stem Cell Res Ther"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2695-7019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T23:50:53Z","timestamp":1765497053000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2695-7019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2695-7019","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,4]]},"published":{"date-parts":[[2025,9,4]]}}}